# Kravis Investment Partners

> Kravis Investment Partners is a VC fund backing Apps, Banking and FinTech. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Jun 2022
- Lead investor: 0%
- Last updated: Aug 2026

Kravis Investment Partners is a VC fund focused on Apps and Banking. Kravis Investment Partners

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Apps | 1 | 25% |
| Banking | 1 | 25% |
| FinTech | 1 | 25% |
| Finance | 1 | 25% |
| Health Care | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 50% |
| Series B | 1 | 25% |
| Series D | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stashfin | StashFin is a digital lending venture that offers online applications for personal loans, providing simple and fast approval and disbursal for loans. It was started by a team of former financial services professionals who have more than 40 years of experience in consumer finance and capital markets.It was founded in 2016 and headquartered in NewDelhi. | $70M | Series C | Jun 21, 2022 |  |
| Stashfin | StashFin is a digital lending venture that offers online applications for personal loans, providing simple and fast approval and disbursal for loans. It was started by a team of former financial services professionals who have more than 40 years of experience in consumer finance and capital markets.It was founded in 2016 and headquartered in NewDelhi. | $40M | Series B | Apr 02, 2021 |  |
| ORIC Pharmaceuticals | ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $55M | Series D | Aug 09, 2019 |  |
| ORIC Pharmaceuticals | ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $50M | Series C | Feb 21, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [Altara Ventures](https://shizune.co/investors/profile/altara-ventures) — VC Fund, 2 deals together
- EcoR1 Capital — VC Fund, 2 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 2 deals together
- Memorial Sloan - Kettering Cancer Center — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Snow Leopard Technology Ventures](https://shizune.co/investors/profile/snow-leopard-technology-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Kravis Investment Partners invest in?

Kravis Investment Partners invests primarily in Apps, Banking and FinTech startups, most often at Series C and Series B stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kravis Investment Partners last invest?

The most recent investment recorded for Kravis Investment Partners closed in Jun 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co